RecruitingPhase 4NCT07135427

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

Genetic Variation in IgG as a Mechanism for Immune Deficiency and Exacerbations in AATD


Sponsor

University of Alabama at Birmingham

Enrollment

30 participants

Start Date

Sep 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how genetic differences in the immune system affect the response to a pneumococcal (pneumonia) vaccine in people who carry a particular genetic variant called the SERPINA1 Z allele, which is associated with alpha-1 antitrypsin deficiency — a hereditary condition that can cause lung and liver disease. **You may be eligible if...** - You are an adult who carries one copy of the SERPINA1 Z gene variant (heterozygous) - You have either had no COPD flare-ups in the past year, or you have had 2 or more flare-ups - You have not received a pneumococcal conjugate vaccine in the past 5 years, OR you have only received the older polysaccharide-type vaccine **You may NOT be eligible if...** - You have received a pneumococcal conjugate vaccine within the past 5 years - You have a known allergy or severe reaction to pneumococcal conjugate vaccines Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICAL20-valent pneumococcal conjugate vaccine

Administration of PCV20


Locations(1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07135427


Related Trials